- Conditions
- Arthritis, Rheumatoid
- Interventions
- Sirukumab 100 mg, Sirukumab 50 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,820 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 63 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1825–1848
of 10,564
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- Xanomeline/Trospium Chloride, Placebo
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 32
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Observational study
- Other
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 3 Years to 18 Years · Male only
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- Sacramento, California • Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Hypercholesterolemia
- Interventions
- Lapaquistat acetate and stable statin therapy, Stable statin therapy
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 649 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 13
- States / cities
- Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more
- Conditions
- Binge Eating Disorder
- Interventions
- Lisdexamfetamine dimesylate, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 39
- States / cities
- Fort Myers, Florida • Lauderhill, Florida • Leesburg, Florida + 35 more
- Conditions
- Fibrillation, Atrial
- Interventions
- omega-3-acid ethyl esters, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 178
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 149 more
- Conditions
- Advanced Adult Hepatocellular Carcinoma
- Interventions
- Dalantercept plus sorafenib
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Westwood, Kansas • Boston, Massachusetts + 4 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase, Biospecimen Collection, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Lestaurtinib, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Pegaspargase, Pharmacological Study, Prednisone, Therapeutic Hydrocortisone, Vincristine Sulfate
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 1 Year
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 120 more
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Lenalidomide
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 44
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- ampreloxetine, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 23
- States / cities
- Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more
- Conditions
- Stroke, Ischemic, Motor Activity, Upper Extremity Paralysis
- Interventions
- Sham, Low dose tDCS, High dose tDCS, mCIMT
- Device · Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Molnupiravir, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,441 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 53 more
- Conditions
- Heterozygous Familial Hypercholesterolaemia
- Interventions
- AZD0780, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Garden Grove, California • San Diego, California • Miami Lakes, Florida + 16 more
- Conditions
- Angioplasty, Transluminal, Percutaneous Coronary
- Interventions
- Otamixaban (XRP0673), Unfractionated Heparin, Percutaneous Coronary Intervention
- Drug · Procedure
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 947 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 37
- States / cities
- Los Angeles, California • Santa Ana, California • Washington D.C., District of Columbia + 31 more
- Conditions
- Breast Inflammatory Carcinoma
- Interventions
- Biospecimen Collection, Olaparib, Radiation Therapy, Survey Administration
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 214
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 174 more
- Conditions
- Cryptosporidiosis, HIV Infections
- Interventions
- Paromomycin sulfate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Miami, Florida • Chicago, Illinois + 7 more
- Conditions
- Alzheimers Disease
- Interventions
- CNP520 50mg, CNP520 15mg, Matching placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 1,145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 95
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Interventions
- ZoMaxx™ Drug-Eluting Coronary Stent System, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,099 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 74
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • La Jolla, California + 60 more
- Conditions
- Pediatric Recipients of a Liver Transplant
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Chicago, Illinois • New York, New York + 2 more
- Conditions
- Heart Failure, Congestive
- Interventions
- DITPA (3,5-diiodothyropropionic acid), Placebo
- Drug
- Lead sponsor
- Titan Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 22
- States / cities
- Huntsville, Alabama • Peoria, Arizona • Tucson, Arizona + 18 more
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
- Conditions
- Unresectable Stage III, Stage IV Melanoma
- Interventions
- Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 76 more
- Conditions
- Chronic Hepatitis C
- Interventions
- SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir), Ribavirin
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more
- Conditions
- Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia
- Interventions
- HGF plasmid
- Genetic
- Lead sponsor
- AnGes USA, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more